Evidence map›Paper›PMID 18991718›Full record

ReviewCurrent pharmaceutical design2008

Imaging virus-associated cancer.

De-Xue Fu, Catherine A Foss, Sridhar Nimmagadda, Richard F Ambinder, Martin G Pomper

Abstract readReview
In one paragraph

Review in Current pharmaceutical design, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

De-Xue FuSidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.
Catherine A Foss
Sridhar Nimmagadda
Richard F Ambinder
Martin G Pomper
Johns Hopkins University · US

Funding

Treatment of lymphoma by death receptor induced apoptosisP50CA096888 · NCI · JOHNS HOPKINS UNIVERSITY · PI AMBINDER, RICHARD FREDERICK · 2002 to 2009
$13.6M
Role of KSHV in AIDS MalignanciesP01CA113239 · NCI · JOHNS HOPKINS UNIVERSITY · PI HAYWARD, GARY S · 2006 to 2010
$5.8M
Small Animal Imaging Resource (SAIR)U24CA092871 · NCI · JOHNS HOPKINS UNIVERSITY · PI POMPER, MARTIN G · 2007 to 2011
$2.3M
NCI NIH HHS P01 CA113239NCI NIH HHS P50 CA096888NCI NIH HHS P50 CA96888NCI NIH HHS U24 CA092871NCI NIH HHS U24 CA92871
6 · The paper itself

Abstract

Cancer remains an important and growing health problem. Researchers have made great progress in defining genetic and molecular alterations that contribute to cancer formation and progression. Molecular imaging can identify appropriate patients for targeted cancer therapy and may detect early biochemical changes in tumors during therapy, some of which may have important prognostic implications. Progress in this field continues largely due to a union between molecular genetics and advanced imaging technology. This review details uses of molecular-genetic imaging in the context of tumor-associated viruses. Under certain conditions, and particularly during pharmacologic stimulation, gammaherpesviruses will express genes that enable imaging and therapy in vivo. The techniques discussed are readily translatable to the clinic.

Indexed as

AnimalsAntineoplastic AgentsDrug Delivery SystemsGammaherpesvirinaeGenes, ViralHerpesviridae InfectionsHumansMolecular BiologyNeoplasmsRadionuclide ImagingRadiopharmaceuticalsTumor Virus InfectionsAntineoplastic AgentsRadiopharmaceuticals

Identifiers

PMID18991718
PMCPMC3369625
OpenAlexW2150825363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.